Literature DB >> 3877565

Invasiveness of T-cell hybridomas in vitro and their metastatic potential in vivo.

E Roos, G La Rivière, J G Collard, M J Stukart, P De Baetselier.   

Abstract

BW5147 lymphoma cells, which are noninvasive and nonmetastatic, were fused with normal T-lymphocytes. The invasiveness of the generated T-cell hybridomas was tested in hepatocyte cultures, and their metastatic potential was tested by tail vein injection. A total of 29 hybridomas generated from alloantigen-activated T-cells were all found to be invasive. One of these cell lines rapidly lost invasiveness in culture. Most hybridomas generated from nonstimulated spleen T-cells were also invasive, but 5 of 27 were not. Six invasive and four noninvasive hybridomas were injected into the tail vein of syngeneic mice. All invasive cell lines caused extensive and widespread tumor growth, particularly in the liver, which was usually severalfold enlarged; the spleen; kidneys; and ovaries. In contrast the noninvasive hybrids, which were tumorigenic upon s.c. injection, did not form any metastases. We conclude that properties derived from normal T-cells, when introduced into noninvasive T-lymphoma cells, cause them to become invasive as well as metastatic. Furthermore for this tumor cell type invasiveness as measured in hepatocyte cultures appears to be closely associated with the ability to colonize organs from the bloodstream.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877565

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Differential presentation of hepatitis B S-preS(2) particles and peptides by macrophages and B-cell like antigen-presenting cells.

Authors:  J P Scheerlinck; G Burssens; L Brys; A Michel; P Hauser; P De Baetselier
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Interaction of B-cell hybridomas with fibroblast or hepatocyte monolayers in vitro and their metastatic behaviour in vivo.

Authors:  S Verhaegen; H Verschueren; J Brissinck; D Van Hecke; D Dekegel; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

3.  Tumour necrosis factor-alpha stimulates invasiveness of T-cell hybridomas and cytotoxic T-cell clones by a pertussis toxin-insensitive mechanism.

Authors:  G La Rivière; J W Klein Gebbinck; C A Schipper; E Roos
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

4.  Effect of cell fusion on metastatic ability of mouse hepatocarcinoma cell lines.

Authors:  Yan Ji; Mao-Ying Ling; Ying Li; Hong Xie
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

Review 5.  Adhesion molecules in lymphoma metastasis.

Authors:  E Roos
Journal:  Cancer Metastasis Rev       Date:  1991-05       Impact factor: 9.264

6.  Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma.

Authors:  I S Zeelenberg; L Ruuls-Van Stalle; E Roos
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

7.  Induction of invasive and metastatic potential in mouse T-lymphoma cells (BW5147) by treatment with 5-azacytidine.

Authors:  G G Habets; R A van der Kammen; E H Scholtes; J G Collard
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

8.  Melanoma x macrophage hybrids with enhanced metastatic potential.

Authors:  M Rachkovsky; S Sodi; A Chakraborty; Y Avissar; J Bolognia; J M McNiff; J Platt; D Bermudes; J Pawelek
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

Review 9.  GnT-V, macrophage and cancer metastasis: a common link.

Authors:  A K Chakraborty; J M Pawelek
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 10.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.